Combination therapy in pulmonary arterial hypertension: Do we have the right strategy?

Expert Review of Respiratory Medicine

Volumn 5, Issue 2, 2011, Pages 191-205

  Mukherjee, Bhashkar ^a   Howard, Luke ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

combination therapy; de novo therapy; goal oriented approach; pulmonary hypertension

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTACYCLIN; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VASODILATOR AGENT; WARFARIN;

ADD ON THERAPY; AIRWAY REMODELING; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; LUNG HEMODYNAMICS; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 79955456078     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.13     Document Type: Review

References (108)

1. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results form a national registry. Am. J. Respir. Crit. Care Med. 173, 1023-1030 (2006).
2. Peacock AJ, Murphy NF, McMurray JV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30, 104-109 (2007). (Pubitemid 47074013)
3. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J. Am. Coll. Cardiol. 51(16), 1527-1538 (2008). (Pubitemid 351508372)
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351(14), 1425-1436 (2004).
5. Rich S, Pogoriler J, Husain AL, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 138(5), 1234-1239 (2010).
6. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 35, 1079-1087 (2010).
7. Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122, 156-163 (2010).
8. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122, 164-172 (2010).
9. Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. 2009 Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 34(6), 1219-1263 (2009).
10. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA.ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16), 2250-2294 (2009).
11. Gibbs JS. Treating pulmonary arterial hypertension: is it worth it? Heart 96, 1607-1608 (2010).
12. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135, 794-804 (2009).
13. Ghofrani HA, Barst RJ, Benza RL et al. Future perspectives for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S108-S117 (2009).
14. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115, 343-349 (1991).
15. Voelkel NF, Quaife RA, Leinwand LA et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114, 1883-1891 (2006). (Pubitemid 44673364)
16. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76(1), 135-141 (1987). (Pubitemid 17093201)
17. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 175, 846-850 (2007). (Pubitemid 46631797)
18. Handoko ML de Man FS, Allaart CP et al. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur. Respir. Rev. 19(115), 72-82 (2010).
19. Kasimir MT. Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur. J. Cardiothorac. Surg. 26(4), 776-781 (2004).
20. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6(6), 698-702 (2000). (Pubitemid 30398796)
21. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 26(2), 194-201 (2002). (Pubitemid 34107873)
22. Yang Z, Krasnici N, Lüscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100(1), 5-8 (1999). (Pubitemid 29297932)
23. Wharton J, Strange JW, Moller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 172(1), 105-113 (2005). (Pubitemid 40923321)
24. Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182(9), 1171-1177 (2010).
25. Klein M, Schermuly RT, Ellinghaus P et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodelling. Circulation 118(20), 2081-2090 (2008).
26. Chintalgattu V, Ai D, Langley RR et al. Cardiomyocyte PDGFR-b signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120(2), 472-484 (2010).
27. Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3), 238-248 (2007). (Pubitemid 47196559)
28. Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 171(11), 1292-1297 (2005). (Pubitemid 40740738)
29. van Wolferen SA, Boonstra A, Marcus JT et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 92(12), 1860-1861 (2006). (Pubitemid 44851345)
30. Bogaard HJ, Natarajan R, Mizuno S et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am. J. Respir. Crit. Care Med. 182, 652-660 (2010).
31. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts. Circulation 121, 2045-2066 (2010).
32. Handoko ML, Lamberts RR, Redout EM et al. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am. J. Physiol. Heart Circ. Physiol. 297, H1752-H1759 (2009).
33. Galie N, Manes A, Negro L, Palazzini M, Bacchia-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30, 394-403 (2009).
34. Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir. Res. 11, 12 (2010).
35. Macchia A, Marchioli R, Marfisi R et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 153, 1037-1047 (2007). (Pubitemid 46809838)
36. Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am. Heart J. 159(2), 245-257 (2010).
37. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296-302 (1996).
38. Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327, 70-75 (1992).
39. Tuder RM, Cool CD, Gearci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159, 1925-1932 (1999). (Pubitemid 29275065)
40. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121(6), 409-415 (1994).
41. Simonneau G, Barst RJ, Galie N et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(6), 800-804 (2002). (Pubitemid 34229650)
42. Olschewski H, Simonneau G, Galiè N et al. Aerosolized iloprost randomized study group. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322-329 (2002). (Pubitemid 34815354)
43. Vizza CD, Sciomer S, Morelli S et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 86(6), 661-665 (2001). (Pubitemid 33086884)
44. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 31(4), 891-901 (2008).
45. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102, 2434-2440 (2000).
46. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288), 1119-1123 (2001). (Pubitemid 32971843)
47. Galiè N, Olschewski H, Oudiz RJ et al. Ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy studies (ARIES) group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010-3019 (2008).
48. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J. 29(16), 1936-1948 (2008).
49. Barst RJ, Langleben D, Frost A et al. STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441-447 (2004). (Pubitemid 38187114)
50. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur. Respir. J. 5, 757-762 (1992).
51. Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group. sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005). (Pubitemid 41653106)
52. Galiè N, Brundage BH, Ghofrani HA et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) study group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009).
53. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N. Engl. J. Med. 361(19), 1864-1871 (2009).
54. Gokhman R, Smithburger PL, Kane-Gill SL, Seybert AL. Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension. J. Cardiovasc. Pharmacol. 56(6), 686-695 (2010).
55. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. 60(1), 107-112 (2005). (Pubitemid 40942789)
56. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol. 64(1), 43-50 (2008).
57. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93, 280-291 (2003). (Pubitemid 37048240)
58. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L480-L487 (2005). (Pubitemid 40229513)
59. Girgis RE, Champion HC, Diette GB et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am. J. Respir. Crit. Care Med. 172, 352-357 (2005). (Pubitemid 41026146)
60. Gruenig E, Michelakis E, Vachiéry JL et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J. Clin. Pharmacol. 49(11), 1343-1352 (2009).
61. Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 27, 89-95 (2006).
62. Galiè N, Rubin LJ, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008). (Pubitemid 351902178)
63. Ghofrani HA, Wilkins MR, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118, 1195-1201 (2008).
64. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174(11), 1257-1263 (2006). (Pubitemid 44924827)
65. Simonneau G, Rubin LJ, Galiè N et al.; for the PACES study group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 149, 521-530 (2008).
66. McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55(18), 1915-1922 (2010).
67. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28(4), 691-694 (2006). (Pubitemid 46331988)
68. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 48(7), 1433-1437 (2006). (Pubitemid 44436826)
69. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136(7), 515-522 (2002). (Pubitemid 34252285)
70. Ghofrani HA, Rose F, Schermuly RT et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit. Care Med. 30(11), 2489-2492 (2002). (Pubitemid 35351868)
71. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42(1), 158-164 (2003). (Pubitemid 36760778)
72. Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24(3), 353-359 (2004). (Pubitemid 39232254)
73. Coghlan JG, Pope J, Denton CP. Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. Curr. Opin. Pulm. Med. 16(Suppl. 1), S27-S34 (2010).
74. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 26(5), 858-863 (2005). (Pubitemid 41632043)
75. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4), 780-788 (2002). (Pubitemid 34925627)
76. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106(3), 319-324 (2002). (Pubitemid 34778955)
77. Benza RL, Gupta H, Soto F et al. Clinical Worsening Of Pulmonary Arterial Hypertension: The COMPASS-3 Study. ClinicalTrials.gov Identifier: NCT00433329. Am. J. Respir. Crit. Care Med. 181, A2512 (2010).
78. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 114(13), 1417-1431 (2006). (Pubitemid 44454562)
79. Hoeper MM. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value. Eur. Respir. J. 29, 432-434 (2007). (Pubitemid 46372086)
80. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114(14), 1482-1489 (2006). (Pubitemid 44527003)
81. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am. J. Respir. Crit. Care Med. 155(4), 1278-1282 (1997). (Pubitemid 27172771)
82. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002). (Pubitemid 34984638)
83. Kuwano K, Hashino A, Asaki T et al. 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J. Pharmacol. Exp. Ther. 322(3), 1181-1188 (2007). (Pubitemid 47295780)
84. Grimminger F, Weimann G, Frey R et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 33(4), 785-792 (2009).
85. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a Phase II study. Eur. Respir. J. 36(4), 792-799 (2010).
86. Klein M et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118, 2081-2090 (2008).
87. Gomberg-Maitland M, Maitland ML, Barst RJ et al. A dosing/cross- development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 87(3), 303-310 (2010).
88. Hoeper MM, Taha N, Bekjarova A et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur. Respir. J. 22(2), 330-334 (2003). (Pubitemid 36987006)
89. Seyfarth HJ, Pankau H, Hammerschmidt S et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 128(2), 709-713 (2005). (Pubitemid 41140500)
90. Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 134(1), 139-145 (2008). (Pubitemid 352008775)
91. Akagi S, Matsubara H, Miyaji K et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ. J. 72(7), 1142-1146 (2008). (Pubitemid 351957082)
92. Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J. Heart Lung Transplant. 28(3), 280-284 (2009).
93. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am. J. Cardiol. 96(9), 1334-1336 (2005). (Pubitemid 41505420)
94. Ruiz MJ, Escribano P, Delgado JF et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J. Heart Lung Transplant. 25(11), 1353-1357 (2006). (Pubitemid 44692511)
95. Reichenberger F, Voswinckel R, Steveling E et al. Sildenafil treatment for portopulmonary hypertension. Eur. Respir. J. 28(3), 563-567 (2006). (Pubitemid 44794671)
96. Voswinckel R, Reichenberger F, Enke B et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm. Pharmacol. Ther. 21(5), 824-832 (2008).
97. Kim SY, Shim JK, Shim YH, Hong SW, Choi KH, Kwak YL. Sildenafil and beraprost combination therapy in patients with pulmonary hypertension undergoing valvular heart surgery. J. Heart Valve Dis. 19(3), 333-340 (2010).
98. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24(6), 1007-1010 (2004). (Pubitemid 39642293)
99. Lunze K, Gilbert N, Mebus S et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J. Clin. Invest. 36(Suppl. 3), 32-38 (2006). (Pubitemid 44179779)
100. Mathai SC, Girgis RE, Fisher MR et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J. 29(3), 469-475 (2007). (Pubitemid 46372092)
101. Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can. Respir. J. 15(8), 427-430 (2008).
102. A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2) http://clinicaltrials.gov/ct2/show/NCT00887978
103. FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) http://clinicaltrials.gov/ ct2/show/NCT00325442
104. Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (COMPASS 2) http://clinicaltrials.gov/ct2/show/NCT00303459
105. GRIPHON: A Multicenter, Double-blind, Placebo-controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients With Pulmonary Arterial Hypertension http://clinicaltrials.gov/ct2/show/NCT01106014
106. A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) http://clinicaltrials.gov/ct2/show/ NCT00810693
107. Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension (ATHENA-1) http://clinicaltrials.gov/ct2/ show/NCT00617305
108. A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (AMBITION) http://clinicaltrials.gov/ct2/show/NCT01178073